Shanghai Henlius Biotech, Inc. provided unaudited consolidated earnings guidance for the year ended December 31, 2023. The board is expected that the company will record a profit for the year of no less than RMB 500 million for the Reporting Period. This is the first time for Henlius to achieve full-year profits following the company's achievement of its first half-year profits for the six months ended 30 June 2023.

The full year of profitability is primarily contributed by the continuous growth in sales revenue of the company's core products HANQUYOU and HANSIZHUANG, as well as cost reduction and efficiency improvement through refined management.